Wen‐Shuo Wu

Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis

Mark C. Genovese, Josef S Smolen, Tsutomu Takeuchi et al. · The Lancet Rheumatology · 2020 · 80 citations

Rheumatoid Disorder, Rheumatology, Integrated Safety Analysis +10

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis

Masayoshi Harigai, Kevin Winthrop, Tsutomu Takeuchi et al. · RMD Open · 2020 · 75 citations · Full text

Overexpression of RhoA is associated with poor prognosis in hepatocellular carcinoma

X.R. Li, Feiyang Ji, Jun Ouyang et al. · European Journal of Surgical Oncology · 2006 · 62 citations

Tumor Biology, Hepatology, Medicine +7

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

Julio Rosenstock, Stanley H. Hsia, Luis Nevárez Ruiz et al. · New England Journal of Medicine · 2025 · 46 citations

Predictive factors for EGFR -tyrosine kinase inhibitor retreatment in patients with EGFR -mutated non-small-cell lung cancer – A multicenter retrospective SEQUENCE study

Gee‐Chen Chang, Chien‐Hua Tseng, Kuo-Hsuan Hsu et al. · Lung Cancer · 2016 · 28 citations

Non-small-cell Lung Cancer, Medicine, Predictive Factors +7